Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial

Clicks: 535
ID: 112934
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
NCT02149121.
Reference Key
ch2019biodrugslong-term Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Suh CH;Yoo DH;Berrocal Kasay A;Chalouhi El-Khouri E;Cons Molina FF;Shesternya P;Miranda P;Medina-Rodriguez FG;Wiland P;Jeka S;Chavez-Corrales J;Linde T;Hrycaj P;Abello-Banfi M;Hospodarskyy I;Jaworski J;Piotrowski M;Brzosko M;Krogulec M;Shevchuk S;Calvo A;Andersone D;Park W;Shim SC;Lee SJ;Lee SY;;
Journal biodrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Year 2019
DOI
DOI not found
URL
https://www.pubmed.gov/30719632/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine adult female male adolescent aged middle aged young adult Drug Administration Schedule Clinical Trial Phase III Randomized Controlled Trial Antibodies Monoclonal Double-Blind Method Multicenter Study dae hyun yoo arthritis rheumatoid / drug therapy* murine-derived / adverse effects rituximab / administration & dosage* pmid:30719632 pmc6373391 doi:10.1007/s40259-018-00331-4 chang-hee suh sung young lee murine-derived / administration & dosage* antirheumatic agents / administration & dosage* biosimilar pharmaceuticals / administration & dosage* biosimilar pharmaceuticals / adverse effects blood sedimentation / drug effects methotrexate / administration & dosage patient reported outcome measures rituximab / adverse effects

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.